Jump to content
Aaron Kesselheim, M.D., J.D., M.P.H.
Return to 113 Ethics Grand Rounds: " ETHICAL USE OF SURROGATE MEASURES IN ACCELERATED APPROVAL: ADUCANUMAB AND BEYOND " (011122)
Aaron S. Kesselheim MD JD MPH is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent (non-industry-funded) academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials. Aaron is a core faculty member at the HMS Center for Bioethics, where he co-teaches a course on health policy, law, and bioethics and organizes a monthly policy and ethics seminar series. Aaron also serves as the Sidley Austin-Robert D. McLean Visiting Professor of Law at Yale Law School, where he teaches a yearly course on Food and Drug Administration Law and Policy (and at the Yale School of Public Health). He recently developed a massive open online course called Prescription Drug Regulation, Cost, and Access: Current Controversies in Context disseminated via the HarvardX platform to over 95,000 participants world-wide (and still available for viewing here: https://www.edx.org/course/the-fda-and-prescription-drugs-current-controversies-in-context). He is the editor-in-chief of the Journal of Law, Medicine, and Ethics. In 2020, he was elected to the National Academy of Medicine.